CY1106601T1 - Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου - Google Patents
Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινουInfo
- Publication number
- CY1106601T1 CY1106601T1 CY20071100670T CY071100670T CY1106601T1 CY 1106601 T1 CY1106601 T1 CY 1106601T1 CY 20071100670 T CY20071100670 T CY 20071100670T CY 071100670 T CY071100670 T CY 071100670T CY 1106601 T1 CY1106601 T1 CY 1106601T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gemcitabine
- ionizing radiation
- cancer
- treatment
- optionally
- Prior art date
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title abstract 6
- 229960005277 gemcitabine Drugs 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000005865 ionizing radiation Effects 0.000 title abstract 3
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000002137 anti-vascular effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μία μέθοδο για την παραγωγή ενός αντι-αγγειογόνου και/ή μείωσης της αγγειακής διαπερατότητας αποτελέσματος σ' ένα θερμόαιμο ζώο όπως ο άνθρωπος, που υποβάλλεται σε θεραπεία προαιρετικά με ιοντίζουσα ακτινοβολία, ειδικότερα μία μέθοδο για τη θεραπευτική αντιμετώπιση ενός καρκίνου, ειδικότερα ενός καρκίνου που συμπεριλαμβάνει ένα συμπαγή όγκο, η οποία περιλαμβάνει τη χορήγηση ZD6474 σε συνδυασμό μ' ένα γκεμσιταμπίνη· σε μία φαρμακευτική σύνθεση που περιέχει ZD6474 και γκεμσιταμπίνη· σ' ένα συνδυασμένο προϊόν που περιέχει ZD6474 και γκεμσιταμπίνη για χρήση σε μία μέθοδο θεραπευτικής αγωγής σε σώμα ανθρώπου ή ζώου· σ' ένα κιτ που περιλαμβάνει ZD6474 και γκεμσιταμπίνη· στη χρήση του ZD6474 και γκεμσιταμπίνης στην παρασκευή ενός φαρμάκου για χρήση στην παραγωγή ενός αντιαγγειογόνου και/ή μείωσης της αγγειακής διαπερατότητας αποτελέσματος σ' ένα θερμόαιμο ζώο όπως ο άνθρωπος, που προαιρετικά υποβάλλεται σε θεραπεία με ιοντίζουσα ακτινοβολία.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0223380.7A GB0223380D0 (en) | 2002-10-09 | 2002-10-09 | Combination therapy |
PCT/GB2003/004334 WO2004032937A1 (en) | 2002-10-09 | 2003-10-06 | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106601T1 true CY1106601T1 (el) | 2012-01-25 |
Family
ID=9945538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100670T CY1106601T1 (el) | 2002-10-09 | 2007-05-17 | Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060009418A1 (el) |
EP (1) | EP1551409B1 (el) |
JP (2) | JP5416328B2 (el) |
KR (1) | KR101098061B1 (el) |
CN (1) | CN100363004C (el) |
AT (1) | ATE357236T1 (el) |
AU (1) | AU2003269253B2 (el) |
BR (1) | BR0315088A (el) |
CA (1) | CA2501651C (el) |
CY (1) | CY1106601T1 (el) |
DE (1) | DE60312715T2 (el) |
DK (1) | DK1551409T3 (el) |
ES (1) | ES2282656T3 (el) |
GB (1) | GB0223380D0 (el) |
HK (1) | HK1078771A1 (el) |
IL (1) | IL167633A (el) |
MX (1) | MXPA05003595A (el) |
NO (1) | NO330601B1 (el) |
NZ (1) | NZ538999A (el) |
PT (1) | PT1551409E (el) |
SI (1) | SI1551409T1 (el) |
WO (1) | WO2004032937A1 (el) |
ZA (1) | ZA200502753B (el) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ518028A (en) | 1999-11-05 | 2004-03-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
EP1777218B1 (en) | 2000-10-20 | 2008-12-31 | Eisai R&D Management Co., Ltd. | Process for the preparation of 4-phenoxy quinoline derivatives |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
JP4593464B2 (ja) | 2002-11-04 | 2010-12-08 | アストラゼネカ アクチボラグ | Srcチロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
AU2004212255B2 (en) * | 2003-02-13 | 2007-07-05 | Astrazeneca Ab | Combination therapy of ZD6474 with 5-FU or/and CPT-11 |
JPWO2004080462A1 (ja) | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | c−Kitキナーゼ阻害剤 |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
NZ544458A (en) * | 2003-07-10 | 2009-04-30 | Astrazeneca Ab | Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
KR20070053205A (ko) | 2004-09-17 | 2007-05-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 의약 조성물 |
BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
CA2614002A1 (en) * | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
US20080219977A1 (en) * | 2005-07-27 | 2008-09-11 | Isaiah Josh Fidler | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
BRPI0620140A2 (pt) * | 2005-12-22 | 2011-11-01 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e pemetrexed, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular |
CN101443009A (zh) | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
JPWO2008088088A1 (ja) | 2007-01-19 | 2010-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 膵癌治療用組成物 |
KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
US20120070368A1 (en) * | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
EP2586443B1 (en) | 2010-06-25 | 2016-03-16 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
KR101762999B1 (ko) | 2011-04-18 | 2017-07-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료제 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
RU2658601C2 (ru) | 2013-05-14 | 2018-06-21 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба |
MX2017001980A (es) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
KR20170122734A (ko) | 2015-02-25 | 2017-11-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
WO2016204193A1 (ja) | 2015-06-16 | 2016-12-22 | 株式会社PRISM Pharma | 抗がん剤 |
CN106619688A (zh) * | 2016-12-27 | 2017-05-10 | 郑州郑先医药科技有限公司 | 一种治疗糖尿病的药物组合物及应用 |
CN106727657A (zh) * | 2016-12-27 | 2017-05-31 | 郑州郑先医药科技有限公司 | 一种治疗糖尿病的西药组合物及应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3587500T2 (de) * | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
NZ518028A (en) * | 1999-11-05 | 2004-03-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
US6953679B2 (en) * | 2000-09-19 | 2005-10-11 | Bristol-Myers Squibb Company | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
CA2495487A1 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
AU2004212255B2 (en) * | 2003-02-13 | 2007-07-05 | Astrazeneca Ab | Combination therapy of ZD6474 with 5-FU or/and CPT-11 |
NZ544458A (en) * | 2003-07-10 | 2009-04-30 | Astrazeneca Ab | Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
CA2614002A1 (en) * | 2005-07-06 | 2007-01-11 | Astrazeneca Ab | Combination therapy of cancer with azd2171 and gemcitabine |
BRPI0620140A2 (pt) * | 2005-12-22 | 2011-11-01 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e pemetrexed, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular |
WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
US20100212978A1 (en) * | 2009-02-23 | 2010-08-26 | Wen-Hung Huang | Bicycle with two operation molds |
-
2002
- 2002-10-09 GB GBGB0223380.7A patent/GB0223380D0/en not_active Ceased
-
2003
- 2003-10-06 KR KR1020057005960A patent/KR101098061B1/ko active IP Right Grant
- 2003-10-06 US US10/530,567 patent/US20060009418A1/en not_active Abandoned
- 2003-10-06 NZ NZ538999A patent/NZ538999A/en not_active IP Right Cessation
- 2003-10-06 ES ES03751032T patent/ES2282656T3/es not_active Expired - Lifetime
- 2003-10-06 BR BR0315088-7A patent/BR0315088A/pt not_active IP Right Cessation
- 2003-10-06 PT PT03751032T patent/PT1551409E/pt unknown
- 2003-10-06 EP EP03751032A patent/EP1551409B1/en not_active Expired - Lifetime
- 2003-10-06 CA CA2501651A patent/CA2501651C/en not_active Expired - Fee Related
- 2003-10-06 WO PCT/GB2003/004334 patent/WO2004032937A1/en active IP Right Grant
- 2003-10-06 DK DK03751032T patent/DK1551409T3/da active
- 2003-10-06 AT AT03751032T patent/ATE357236T1/de active
- 2003-10-06 MX MXPA05003595A patent/MXPA05003595A/es active IP Right Grant
- 2003-10-06 JP JP2004542620A patent/JP5416328B2/ja not_active Expired - Fee Related
- 2003-10-06 SI SI200330784T patent/SI1551409T1/sl unknown
- 2003-10-06 DE DE60312715T patent/DE60312715T2/de not_active Expired - Lifetime
- 2003-10-06 CN CNB2003801011766A patent/CN100363004C/zh not_active Expired - Fee Related
- 2003-10-06 AU AU2003269253A patent/AU2003269253B2/en not_active Ceased
-
2005
- 2005-03-24 IL IL167633A patent/IL167633A/en active IP Right Grant
- 2005-03-29 NO NO20051575A patent/NO330601B1/no not_active IP Right Cessation
- 2005-11-24 HK HK05110642A patent/HK1078771A1/xx not_active IP Right Cessation
-
2006
- 2006-01-17 ZA ZA200502753A patent/ZA200502753B/en unknown
-
2007
- 2007-05-17 CY CY20071100670T patent/CY1106601T1/el unknown
-
2009
- 2009-08-14 US US12/541,647 patent/US20100120708A1/en not_active Abandoned
-
2010
- 2010-12-24 JP JP2010287659A patent/JP2011088921A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1703223A (zh) | 2005-11-30 |
CA2501651C (en) | 2011-02-15 |
KR20050055070A (ko) | 2005-06-10 |
ATE357236T1 (de) | 2007-04-15 |
DK1551409T3 (da) | 2007-06-11 |
HK1078771A1 (en) | 2006-03-24 |
ES2282656T3 (es) | 2007-10-16 |
WO2004032937A1 (en) | 2004-04-22 |
KR101098061B1 (ko) | 2011-12-26 |
US20100120708A1 (en) | 2010-05-13 |
SI1551409T1 (sl) | 2007-08-31 |
DE60312715D1 (de) | 2007-05-03 |
US20060009418A1 (en) | 2006-01-12 |
MXPA05003595A (es) | 2005-06-03 |
JP2011088921A (ja) | 2011-05-06 |
BR0315088A (pt) | 2005-08-16 |
AU2003269253B2 (en) | 2007-04-05 |
IL167633A (en) | 2013-03-24 |
NO20051575L (no) | 2005-04-25 |
PT1551409E (pt) | 2007-05-31 |
NO330601B1 (no) | 2011-05-23 |
CA2501651A1 (en) | 2004-04-22 |
AU2003269253A1 (en) | 2004-05-04 |
JP5416328B2 (ja) | 2014-02-12 |
NZ538999A (en) | 2008-02-29 |
EP1551409B1 (en) | 2007-03-21 |
CN100363004C (zh) | 2008-01-23 |
EP1551409A1 (en) | 2005-07-13 |
JP2006504723A (ja) | 2006-02-09 |
ZA200502753B (en) | 2006-03-29 |
GB0223380D0 (en) | 2002-11-13 |
DE60312715T2 (de) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106601T1 (el) | Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου | |
CY1106259T1 (el) | Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
CY1111565T1 (el) | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
NO20064755L (no) | Kombinasjonsterapi | |
NO20056171L (no) | Kombinasjonsterapi | |
NO20064753L (no) | Kombinasjonsterapi | |
NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
ATE447973T1 (de) | Kombinationstherapie mit azd-2171 | |
DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
DE60308403D1 (de) | Kombinationstherapie mit gemzitabin und zd6126 | |
BRPI0407301A (pt) | Uso de uma combinação, composição farmacêutica, kit, e, método para o tratamento de câncer em um animal de sangue quente tal como um ser humano |